Effects of Angiotensin-Converting Enzyme Inhibition on the Development of the Atrial Fibrillation Substrate in Dogs With Ventricular Tachypacing–Induced Congestive Heart Failure

  • Danshi Li
    From the Departments of Medicine (D.L., K.S., L.P., S.C., Z.W., S.N.) and Pathology (T.K.L.), Montreal Heart Institute and University of Montreal, Montreal, Quebec, Canada.
  • Kaori Shinagawa
    From the Departments of Medicine (D.L., K.S., L.P., S.C., Z.W., S.N.) and Pathology (T.K.L.), Montreal Heart Institute and University of Montreal, Montreal, Quebec, Canada.
  • Li Pang
    From the Departments of Medicine (D.L., K.S., L.P., S.C., Z.W., S.N.) and Pathology (T.K.L.), Montreal Heart Institute and University of Montreal, Montreal, Quebec, Canada.
  • Tack Ki Leung
    From the Departments of Medicine (D.L., K.S., L.P., S.C., Z.W., S.N.) and Pathology (T.K.L.), Montreal Heart Institute and University of Montreal, Montreal, Quebec, Canada.
  • Sophie Cardin
    From the Departments of Medicine (D.L., K.S., L.P., S.C., Z.W., S.N.) and Pathology (T.K.L.), Montreal Heart Institute and University of Montreal, Montreal, Quebec, Canada.
  • Zhiguo Wang
    From the Departments of Medicine (D.L., K.S., L.P., S.C., Z.W., S.N.) and Pathology (T.K.L.), Montreal Heart Institute and University of Montreal, Montreal, Quebec, Canada.
  • Stanley Nattel
    From the Departments of Medicine (D.L., K.S., L.P., S.C., Z.W., S.N.) and Pathology (T.K.L.), Montreal Heart Institute and University of Montreal, Montreal, Quebec, Canada.

抄録

<jats:p> <jats:bold> <jats:italic> <jats:bold> <jats:italic>Background</jats:italic> </jats:bold> </jats:italic> </jats:bold> Atrial structural remodeling creates a substrate for atrial fibrillation (AF), but the underlying signal transduction mechanisms are unknown. This study assessed the effects of ACE inhibition on arrhythmogenic atrial remodeling and associated mitogen-activated protein kinase (MAPK) changes in a dog model of congestive heart failure (CHF). </jats:p> <jats:p> <jats:bold> <jats:italic> <jats:bold> <jats:italic>Methods and Results</jats:italic> </jats:bold> </jats:italic> </jats:bold> Dogs were subjected to various durations of ventricular tachypacing (VTP, 220 to 240 bpm) in the presence or absence of oral enalapril 2 mg · kg <jats:sup>−1</jats:sup> · d <jats:sup>−1</jats:sup> . VTP for 5 weeks induced CHF, local atrial conduction slowing, and interstitial fibrosis and prolonged atrial burst pacing–induced AF. Atrial angiotensin II concentrations and MAPK expression were increased by tachypacing, with substantial changes in phosphorylated forms of c-Jun N-terminal kinase (JNK), extracellular signal–regulated kinase (ERK), and p38-kinase. Enalapril significantly reduced tachypacing-induced changes in atrial angiotensin II concentrations and ERK expression. Enalapril also attenuated the effects of CHF on atrial conduction (conduction heterogeneity index reduced from 3.1±0.4 to 1.9±0.2 ms/mm, <jats:italic>P</jats:italic> <0.05), atrial fibrosis (from 11.9±1.1% to 7.5±0.4%, <jats:italic>P</jats:italic> <0.01), and mean AF duration (from 651±164 to 218±75 seconds, <jats:italic>P</jats:italic> <0.05). Vasodilator therapy of a separate group of VTP dogs with hydralazine and isosorbide mononitrate did not alter CHF-induced fibrosis or AF promotion. </jats:p> <jats:p> <jats:bold> <jats:italic> <jats:bold> <jats:italic>Conclusions</jats:italic> </jats:bold> </jats:italic> </jats:bold> CHF-induced increases in angiotensin II content and MAPK activation contribute to arrhythmogenic atrial structural remodeling. ACE inhibition interferes with signal transduction leading to the AF substrate in CHF and may represent a useful new component to AF therapy. </jats:p>

収録刊行物

  • Circulation

    Circulation 104 (21), 2608-2614, 2001-11-20

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (20)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ